Trials / Withdrawn
WithdrawnNCT06133010
A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
A Phase 2, Observer-Blind, Placebo-Controlled, Proof-of-Concept Trial to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effect of pre-transplant mRNA-1647 on post-transplant cytomegalovirus (CMV) virologic outcomes, anti-CMV antiviral use, and clinical outcomes in CMV-seropositive and CMV-seronegative liver transplant candidates who receive transplants and to assess the safety, reactogenicity, and immunogenicity of mRNA-1647 in all participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | mRNA-1647 | Sterile liquid for injection |
| BIOLOGICAL | Placebo | Sterile liquid for injection |
Timeline
- Start date
- 2024-02-08
- Primary completion
- 2027-02-14
- Completion
- 2027-12-14
- First posted
- 2023-11-15
- Last updated
- 2024-03-15
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06133010. Inclusion in this directory is not an endorsement.